Will Europe Discourage the Launch of New Alzheimer's Drugs? The pharmaceutical industry is under pressure to deliver new therapies for Alzheimer's disease, but the regulatory bureaucracy in Europe coupled with the demand for lower-priced medicines continues to hinder efforts in innovation ... Read more
Thinking of Phase IV Trials? The EU Might See Things Differently… The EU's legislative framework for pharmacovigilance has been significantly boosted over the last year and the latest development is a new consultation on when post-marketing studies should be mandatory. The more leisurely concept of Phase IV efficacy studies looks as if it may be swept aside ... Read more
The Pharm Exec 2013 Pipeline Report: An End to the Gloom? Is the 'lost decade' of declining pipeline productivity finally over? Our annual survey of analyst assessments of the state of drug development suggests so, with subtle shards of sunlight beginning to penetrate the gloom ... Read more
Read the New Pharm Exec Global Digest This month’s issue: how John Dalli’s abrupt departure points to an EC regulation crisis; how Denmark’s Lundbeck is taking on America; brand development in a post-digital world; Takeda’s plans for BRIC ... Read more
